PL2328616T3 - Kompozycje i sposoby dla przeciwciał celujących białko dopełniacza C5 - Google Patents
Kompozycje i sposoby dla przeciwciał celujących białko dopełniacza C5Info
- Publication number
- PL2328616T3 PL2328616T3 PL09737379T PL09737379T PL2328616T3 PL 2328616 T3 PL2328616 T3 PL 2328616T3 PL 09737379 T PL09737379 T PL 09737379T PL 09737379 T PL09737379 T PL 09737379T PL 2328616 T3 PL2328616 T3 PL 2328616T3
- Authority
- PL
- Poland
- Prior art keywords
- compositions
- methods
- complement protein
- antibodies targeting
- targeting complement
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8635508P | 2008-08-05 | 2008-08-05 | |
| EP09737379.9A EP2328616B1 (en) | 2008-08-05 | 2009-08-03 | Compositions and methods for antibodies against complement protein c5 |
| PCT/EP2009/060052 WO2010015608A1 (en) | 2008-08-05 | 2009-08-03 | Compositions and methods for antibodies targeting complement protein c5 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2328616T3 true PL2328616T3 (pl) | 2015-10-30 |
Family
ID=41227252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL09737379T PL2328616T3 (pl) | 2008-08-05 | 2009-08-03 | Kompozycje i sposoby dla przeciwciał celujących białko dopełniacza C5 |
Country Status (39)
| Country | Link |
|---|---|
| US (5) | US8241628B2 (pl) |
| EP (3) | EP2837388A1 (pl) |
| JP (2) | JP5815403B2 (pl) |
| KR (1) | KR101463296B1 (pl) |
| CN (2) | CN104177495B (pl) |
| AR (1) | AR072897A1 (pl) |
| AU (1) | AU2009279197B2 (pl) |
| BR (1) | BRPI0916668B1 (pl) |
| CA (1) | CA2732782C (pl) |
| CL (1) | CL2011000233A1 (pl) |
| CO (1) | CO6351750A2 (pl) |
| CR (2) | CR20110035A (pl) |
| CU (1) | CU23978B1 (pl) |
| DK (1) | DK2328616T3 (pl) |
| EA (1) | EA027575B1 (pl) |
| EC (1) | ECSP11010805A (pl) |
| ES (2) | ES2643411T3 (pl) |
| HK (1) | HK1203156A1 (pl) |
| HN (1) | HN2011000357A (pl) |
| HR (1) | HRP20150799T1 (pl) |
| HU (1) | HUE026179T2 (pl) |
| IL (1) | IL210768B (pl) |
| JO (1) | JO3118B1 (pl) |
| MA (1) | MA32535B1 (pl) |
| MX (2) | MX2011001371A (pl) |
| MY (1) | MY159396A (pl) |
| NZ (2) | NZ590634A (pl) |
| PE (1) | PE20110225A1 (pl) |
| PL (1) | PL2328616T3 (pl) |
| PT (1) | PT2328616E (pl) |
| PY (1) | PY09026846A (pl) |
| RS (1) | RS54113B1 (pl) |
| SG (1) | SG10201405377XA (pl) |
| SI (1) | SI2328616T1 (pl) |
| SV (1) | SV2011003834A (pl) |
| TW (2) | TW201350130A (pl) |
| UA (1) | UA105009C2 (pl) |
| WO (1) | WO2010015608A1 (pl) |
| ZA (1) | ZA201100375B (pl) |
Families Citing this family (158)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104761637B (zh) | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| US7759304B2 (en) | 2006-06-21 | 2010-07-20 | Regents Of The University Of Colorado | Targeting complement factor H for treatment of diseases |
| WO2009023184A2 (en) * | 2007-08-10 | 2009-02-19 | Protelix, Inc. | Universal fibronectin type iii binding-domain libraries |
| US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
| US8680019B2 (en) * | 2007-08-10 | 2014-03-25 | Protelica, Inc. | Universal fibronectin Type III binding-domain libraries |
| ES2595638T3 (es) | 2007-09-26 | 2017-01-02 | Chugai Seiyaku Kabushiki Kaisha | Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| PY09026846A (es) * | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| CA2742802C (en) | 2008-11-10 | 2019-11-26 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
| AR076284A1 (es) | 2009-04-29 | 2011-06-01 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
| WO2011003098A1 (en) | 2009-07-02 | 2011-01-06 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
| CA2795311A1 (en) | 2009-11-05 | 2011-05-12 | Taligen Therapeutics, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis |
| BR112012029067A2 (pt) | 2010-05-14 | 2019-09-24 | Univ Colorado Regents | grupos-alvo de receptor do complemento 2 (cr2) melhorados. |
| SG186397A1 (en) | 2010-06-22 | 2013-01-30 | Univ Colorado Regents | Antibodies to the c3d fragment of complement component 3 |
| AU2011286024B2 (en) * | 2010-08-02 | 2014-08-07 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| EP2647706B1 (en) | 2010-11-30 | 2023-05-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| CA2822288A1 (en) * | 2010-12-22 | 2012-06-28 | Medimmune, Llc | Anti-c5/c5a/c5adesr antibodies and fragments |
| MX352889B (es) | 2011-02-25 | 2017-12-13 | Chugai Pharmaceutical Co Ltd | Anticuerpo de fc especifico para fcyriib. |
| WO2013010955A1 (en) * | 2011-07-15 | 2013-01-24 | Morphosys Ag | Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt) |
| JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| KR20230143201A (ko) | 2011-11-30 | 2023-10-11 | 추가이 세이야쿠 가부시키가이샤 | 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약 |
| ES2728278T3 (es) * | 2011-12-21 | 2019-10-23 | Novartis Ag | Composiciones que comprenden anticuerpos dirigidos al factor P y C5 |
| SG11201404751UA (en) | 2012-02-09 | 2014-09-26 | Chugai Pharmaceutical Co Ltd | Modified fc region of antibody |
| EP3511339B1 (en) * | 2012-02-20 | 2025-04-09 | IPC Research, LLC | Polypeptides binding to human complement c5 |
| AU2013265255B2 (en) | 2012-05-25 | 2018-03-29 | Novartis Ag | Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition |
| US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
| JP2015535212A (ja) | 2012-08-17 | 2015-12-10 | ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト | 補体活性化を検出するための組成物および方法 |
| SG10201709559PA (en) | 2012-08-24 | 2017-12-28 | Chugai Pharmaceutical Co Ltd | Fcγriib-specific fc region variant |
| EP3722320A3 (en) | 2012-10-25 | 2020-12-30 | Bioverativ USA Inc. | Anti-complement c1s antibodies and uses thereof |
| DK2914291T3 (da) | 2012-11-02 | 2022-05-16 | Bioverativ Usa Inc | Anti-komplement-c1s-antistoffer og anvendelser deraf |
| CN104903349B (zh) | 2012-11-08 | 2018-10-19 | 十一生物治疗股份有限公司 | Il-6拮抗剂及其应用 |
| DK2928921T3 (da) * | 2012-12-05 | 2021-04-19 | Novartis Ag | Sammensætninger og fremgangsmåder til antistoffer målrettet epo |
| WO2014119969A1 (ko) * | 2013-01-31 | 2014-08-07 | 서울대학교 산학협력단 | 보체 관련 질환의 예방 및 치료를 위한 c5 항체 및 방법 |
| EP2978451B1 (en) | 2013-03-29 | 2019-11-27 | Alexion Pharmaceuticals, Inc. | Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
| CN105246914B (zh) | 2013-04-02 | 2021-08-27 | 中外制药株式会社 | Fc区变体 |
| SI3011345T1 (sl) | 2013-08-07 | 2017-12-29 | Alexion Pharmaceuticals, Inc. | Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus) |
| MX367423B (es) | 2013-08-28 | 2019-08-21 | Affibody Ab | Polipeptidos de union a c5. |
| BR112016003142A2 (pt) | 2013-08-28 | 2017-10-17 | Swedish Orphan Biovitrum Ab Publ | ligação de polipeptídeos estáveis ao c5 do complemento humano |
| EP3102701A1 (en) | 2014-02-07 | 2016-12-14 | Novartis AG | Impact of genetic factors on disease progression and response to anti-c5 antibody in geographic atrophy |
| ES2824262T3 (es) * | 2014-02-26 | 2021-05-11 | Allergan Inc | Anticuerpos contra componente C5 del complemento |
| EP3973994A1 (en) * | 2014-06-12 | 2022-03-30 | RA Pharmaceuticals, Inc. | Modulation of complement activity |
| US20170327553A1 (en) | 2014-06-25 | 2017-11-16 | Novartis Ag | Compositions and methods for long acting proteins |
| EP3160990A2 (en) | 2014-06-25 | 2017-05-03 | Novartis AG | Compositions and methods for long acting proteins |
| WO2016020791A1 (en) * | 2014-08-05 | 2016-02-11 | Novartis Ag | Ckit antibody drug conjugates |
| JP6594438B2 (ja) | 2014-11-07 | 2019-10-23 | セセン バイオ， インコーポレイテッド | 改善されたｉｌ−６抗体 |
| US11031102B2 (en) | 2014-11-17 | 2021-06-08 | Alexion Pharmaceuticals, Inc. | Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor |
| US20160168237A1 (en) | 2014-12-12 | 2016-06-16 | Alexion Pharmaceuticals, Inc. | Method for treating a complement mediated disorder caused by an infectious agent in a patient |
| KR101860280B1 (ko) | 2014-12-19 | 2018-05-21 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
| BR112017011235A2 (pt) | 2014-12-19 | 2018-02-06 | Chugai Pharmaceutical Co Ltd | anticorpos anti-c5 e métodos de uso |
| CN113956354A (zh) | 2015-01-22 | 2022-01-21 | 中外制药株式会社 | 两种以上抗-c5抗体的组合与使用方法 |
| KR102605798B1 (ko) | 2015-02-05 | 2023-11-23 | 추가이 세이야쿠 가부시키가이샤 | 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용 |
| US20180311299A1 (en) | 2015-05-01 | 2018-11-01 | Alexion Pharmaceuticals, Inc. | Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant |
| CN107922975B (zh) | 2015-08-12 | 2022-06-28 | 诺华股份有限公司 | 治疗眼科病症的方法 |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| WO2017035409A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| EP3359566A1 (en) | 2015-10-07 | 2018-08-15 | Alexion Pharmaceuticals, Inc. | A method for treating age-related macular degeneration in a patient |
| TW201718014A (zh) | 2015-10-12 | 2017-06-01 | 諾華公司 | C5抑制劑於移植相關微血管病之用途 |
| JP7221691B2 (ja) | 2015-10-30 | 2023-02-14 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | Ｔ細胞媒介性同種移植片血管障害の増悪を抑制する方法 |
| HUE065073T2 (hu) * | 2015-12-18 | 2024-04-28 | Chugai Pharmaceutical Co Ltd | Anti-C5 antitestek és alkalmazási eljárások |
| RU2018126297A (ru) * | 2015-12-18 | 2020-01-22 | Новартис Аг | Антитела, нацеленные на cd32b, и способы их применения |
| EP3402816A1 (en) | 2016-01-11 | 2018-11-21 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment |
| CN108718522A (zh) | 2016-02-23 | 2018-10-30 | 赛森生物股份有限公司 | Il-6拮抗剂制剂及其用途 |
| CA3024618A1 (en) | 2016-05-27 | 2017-11-30 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis |
| EP3464351A1 (en) * | 2016-06-07 | 2019-04-10 | Novartis AG | Anti-c5 antibody for treating patients with complement c5 polymorphism |
| EP3463459A1 (en) * | 2016-06-07 | 2019-04-10 | Novartis AG | Tesidolumab for use in the treatment of transplant rejection |
| US20190127453A1 (en) | 2016-06-07 | 2019-05-02 | Novartis Ag | An anti-c5 antibody dosing regimen |
| CN116769024A (zh) | 2016-06-14 | 2023-09-19 | 瑞泽恩制药公司 | 抗c5抗体及其用途 |
| IL263657B2 (en) * | 2016-06-17 | 2025-12-01 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
| EP3494991A4 (en) | 2016-08-05 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES |
| CN110300520B (zh) | 2016-10-12 | 2022-10-04 | 美国比奥维拉迪维股份有限公司 | 抗C1s抗体及其使用方法 |
| WO2018071624A1 (en) | 2016-10-12 | 2018-04-19 | Alexion Pharmaceuticals, Inc. | Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant |
| US11007254B2 (en) | 2016-10-17 | 2021-05-18 | Musc Foundation For Research Development | Compositions and methods for treating central nervous system injury |
| WO2018075758A1 (en) | 2016-10-19 | 2018-04-26 | Alexion Pharmaceuticals, Inc. | A method of quantitating unbound c5 in a sample |
| US20200057046A1 (en) | 2016-10-27 | 2020-02-20 | Alexion Pharmaceuticals, Inc. | Assay for c5b-9 deposition in complement-associated disorders |
| EA039858B1 (ru) * | 2016-11-15 | 2022-03-21 | Ридженерон Фармасьютикалз, Инк. | Антитела против c5 и их применение |
| KR102365871B1 (ko) | 2017-01-31 | 2022-02-21 | 추가이 세이야쿠 가부시키가이샤 | C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법 |
| CN110603252A (zh) | 2017-03-01 | 2019-12-20 | 艾其林医药公司 | 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物 |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| JP7364221B2 (ja) * | 2017-03-06 | 2023-10-18 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 抗ｃ５抗体およびその使用 |
| EP3612561A1 (en) | 2017-04-19 | 2020-02-26 | Alexion Pharmaceuticals, Inc. | Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant |
| JP7194698B2 (ja) | 2017-05-22 | 2022-12-22 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 患者においてタンパク質漏出性腸症を処置するための抗ｃ５抗体の投薬量および投与 |
| KR102806328B1 (ko) * | 2017-07-11 | 2025-05-14 | 알렉시온 파마슈티칼스, 인코포레이티드 | 보체 성분 c5 또는 혈청 알부민에 결합하는 폴리펩티드 및 그의 융합 단백질 |
| EP3661493A4 (en) | 2017-08-02 | 2021-04-14 | Achillion Pharmaceuticals, Inc. | THERAPY PLANS FOR TREATMENT OF PAROXYSMALER NIGHTLY HEMOGLOBINURIA |
| CN118512588A (zh) | 2017-10-26 | 2024-08-20 | 亚力兄制药公司 | 用于治疗阵发性夜间性血红蛋白尿(pnh)和非典型溶血性尿毒症综合征(ahus)的抗c5抗体的剂量和施用 |
| MX2020004921A (es) | 2017-11-29 | 2020-08-27 | Hoffmann La Roche | Ensayo de anticuerpo antifarmaco con supresion de interferencia del objetivo. |
| CA3274059A1 (en) | 2017-12-13 | 2026-03-02 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibody combinations and uses thereof |
| EP3802593B1 (en) | 2018-05-31 | 2024-09-11 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients |
| EP3802603A1 (en) | 2018-06-04 | 2021-04-14 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients |
| CN112654394B (zh) * | 2018-06-19 | 2025-07-11 | 阿塔盖有限责任公司 | 针对补体成分5的抗体分子和其用途 |
| US12312394B2 (en) | 2018-06-28 | 2025-05-27 | Alexion Pharmaceuticals, Inc. | Methods of producing anti-C5 antibodies |
| MY210523A (en) | 2018-08-01 | 2025-09-29 | Univ Osaka | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease |
| US20230022157A1 (en) | 2018-08-20 | 2023-01-26 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement factor d medical disorders |
| JP7653909B2 (ja) | 2018-09-06 | 2025-03-31 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ヒト化抗ｃ５抗体とその利用 |
| WO2020051538A1 (en) | 2018-09-06 | 2020-03-12 | Achillion Pharmaceuticals, Inc. | Morphic forms of complement factor d inhibitors |
| JP7443375B2 (ja) | 2018-09-06 | 2024-03-05 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 医学的障害の治療のための大環状化合物 |
| EP3852874A1 (en) | 2018-09-17 | 2021-07-28 | Kyoto University | Administration of an anti-c5 agent for treatment of hepatic injury or failure |
| US20200095307A1 (en) | 2018-09-21 | 2020-03-26 | Alexion Pharmaceuticals, Inc. | Compositions and methods for the treatment of neuromyelitis optica |
| KR20210093855A (ko) | 2018-09-25 | 2021-07-28 | 아칠리온 파르마세우티칼스 인코포레이티드 | 보체 인자 d 억제제의 형태체 형태 |
| EP3873602B1 (en) | 2018-10-30 | 2023-12-06 | Alexion Pharmaceuticals, Inc. | Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) |
| US20210388070A1 (en) | 2018-10-30 | 2021-12-16 | Alexion Pharmaceuticals, Inc. | Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions |
| US20220002393A1 (en) | 2018-11-20 | 2022-01-06 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis in pediatric patients |
| GB2583560A (en) | 2018-12-11 | 2020-11-04 | Admirx Inc | Fusion protein constructs for complement associated disease |
| WO2020131974A1 (en) | 2018-12-17 | 2020-06-25 | Achillion Pharmaceuticals, Inc. | Targeted dosing for the treatment of complement mediated disorders |
| CN117838856A (zh) | 2019-01-25 | 2024-04-09 | 亚力兄制药公司 | 用于治疗非典型溶血性尿毒综合征(ahus)的抗c5抗体的剂量和施用 |
| EP3924380A1 (en) | 2019-02-14 | 2021-12-22 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of generalized myasthenia gravis |
| BR112021018456A2 (pt) | 2019-03-22 | 2021-11-23 | Achillion Pharmaceuticals Inc | Compostos farmacêuticos para o tratamento de distúrbios mediados por complemento |
| US10963841B2 (en) | 2019-03-27 | 2021-03-30 | On Time Staffing Inc. | Employment candidate empathy scoring system |
| US10728443B1 (en) | 2019-03-27 | 2020-07-28 | On Time Staffing Inc. | Automatic camera angle switching to create combined audiovisual file |
| US20220227851A1 (en) | 2019-05-24 | 2022-07-21 | Alexion Pharmaceuticals, Inc. | Methods of treating vitiligo using an anti-c5 antibody |
| CR20220040A (es) | 2019-07-31 | 2022-03-02 | Hoffmann La Roche | Régimen de dosificación y administración para el tratamiento o prevención de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab |
| KR20240033090A (ko) | 2019-07-31 | 2024-03-12 | 에프. 호프만-라 로슈 아게 | 항-c5 항체 크로발리맙의 사용에 의한 c5-관련 질병의 치료 또는 예방을 위한 투여량 및 투여 섭생 |
| US20220259305A1 (en) | 2019-08-05 | 2022-08-18 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis with eculizumab |
| WO2021034639A1 (en) | 2019-08-16 | 2021-02-25 | Regeneron Pharmaceuticals, Inc. | High concentration anti-c5 formulations |
| US20220370556A1 (en) | 2019-09-27 | 2022-11-24 | Volution Immuno Pharmaceuticals Sa | Method of Treatment |
| US20220356234A1 (en) | 2019-10-02 | 2022-11-10 | Alexion Pharmaceuticals, Inc. | Complement inhibitors for treating drug-induced complement-mediated response |
| CA3153195A1 (en) | 2019-10-25 | 2021-04-29 | John Davis | Dosing regimens for treating or preventing c5-associated diseases |
| US11127232B2 (en) | 2019-11-26 | 2021-09-21 | On Time Staffing Inc. | Multi-camera, multi-sensor panel data extraction system and method |
| KR20220110827A (ko) | 2019-12-09 | 2022-08-09 | 알렉시온 파마슈티칼스, 인코포레이티드 | 시신경척수염 스펙트럼 장애의 치료를 위한 항-c5 항체 |
| JP7734673B2 (ja) | 2019-12-23 | 2025-09-05 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 抗ｃ５抗体を使用して妊娠関連非典型溶血性尿毒症症候群を治療する方法 |
| CN115362162A (zh) | 2020-02-20 | 2022-11-18 | 艾其林医药公司 | 用于治疗补体因子d介导的障碍的杂芳基化合物 |
| US11023735B1 (en) | 2020-04-02 | 2021-06-01 | On Time Staffing, Inc. | Automatic versioning of video presentations |
| EP4135837A1 (en) | 2020-04-16 | 2023-02-22 | Assistance Publique, Hopitaux De Paris | Methods for treating a complement mediated disorder caused by viruses |
| US20230172930A1 (en) | 2020-05-12 | 2023-06-08 | Alexion Pharmaceuticals, Inc. | Use of complement factor d inhibitors alone or in combination with anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria |
| JP2023525581A (ja) | 2020-05-15 | 2023-06-16 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 補体の活性化を検出するための細胞外小胞の使用方法、並びに補体性疾患の処置を評価及び／又は監視するためのその使用 |
| CN113754763B (zh) * | 2020-06-05 | 2024-03-08 | 天辰生物医药(苏州)有限公司 | 分离的抗原结合蛋白及其用途 |
| KR102836238B1 (ko) | 2020-06-16 | 2025-07-18 | 에프. 호프만-라 로슈 아게 | 샘플에서 항체의 유리 항원 측정 방법 |
| CA3173011A1 (en) | 2020-06-24 | 2021-12-30 | Alexion Pharmaceuticals, Inc. | Subcutaneous (sc) administration of anti-c5 antibodies for treatment of complement-associated conditions |
| US20230235035A1 (en) | 2020-07-09 | 2023-07-27 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treating paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients |
| JP7494413B2 (ja) * | 2020-07-15 | 2024-06-04 | ビオシオン インコーポレイテッド | Ｃ５に結合する抗体及びその用途 |
| WO2022036151A1 (en) | 2020-08-13 | 2022-02-17 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma) |
| US11144882B1 (en) | 2020-09-18 | 2021-10-12 | On Time Staffing Inc. | Systems and methods for evaluating actions over a computer network and establishing live network connections |
| EP4213940A1 (en) | 2020-09-21 | 2023-07-26 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treating c5-mediated glomerular nephritis (gn), including lupus nephritis (ln) and/or iga nephropathy (igan) |
| CN116437913A (zh) | 2020-09-23 | 2023-07-14 | 艾其林医药公司 | 用于治疗补体介导的病症的药物化合物 |
| CA3196434A1 (en) | 2020-10-23 | 2022-04-28 | Krista K. JOHNSON | Methods of treating patients having complement disorders using anti-c5 antibodies |
| CN114149501B (zh) * | 2020-12-11 | 2023-05-26 | 天士力生物医药股份有限公司 | 抗c5抗体及其应用 |
| EP4281472A1 (en) | 2021-01-22 | 2023-11-29 | Alexion Pharmaceuticals, Inc. | Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody |
| EP4351735A4 (en) * | 2021-06-07 | 2025-07-30 | Janssen Biotech Inc | MATERIALS AND METHODS FOR DIFFERENTIATION OF CREB-REGULATED TRANSCRIPTION COACTIVATOR 3 |
| WO2022265915A1 (en) | 2021-06-14 | 2022-12-22 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treating dermatomyositis (dm) |
| US20250154232A1 (en) | 2021-07-14 | 2025-05-15 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of myasthenia gravis |
| US11727040B2 (en) | 2021-08-06 | 2023-08-15 | On Time Staffing, Inc. | Monitoring third-party forum contributions to improve searching through time-to-live data assignments |
| WO2023023220A1 (en) | 2021-08-20 | 2023-02-23 | Alexion Pharmaceuticals, Inc. | Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor |
| US11423071B1 (en) | 2021-08-31 | 2022-08-23 | On Time Staffing, Inc. | Candidate data ranking method using previously selected candidate data |
| US20230203176A1 (en) | 2021-09-17 | 2023-06-29 | Novartis Ag | Methods For Prevention Of Graft Rejection In Xenotransplantation |
| US20240415980A1 (en) | 2021-10-28 | 2024-12-19 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-related methods and compositions for knocking out c5 |
| WO2024108529A1 (en) * | 2022-11-25 | 2024-05-30 | Linno Pharmaceuticals Inc. | Properdin binding protein and use thereof |
| US11907652B2 (en) | 2022-06-02 | 2024-02-20 | On Time Staffing, Inc. | User interface and systems for document creation |
| EP4583911A1 (en) | 2022-09-06 | 2025-07-16 | Alexion Pharmaceuticals, Inc. | Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma) |
| TW202426048A (zh) | 2022-09-06 | 2024-07-01 | 美商阿雷希昂製藥公司 | 用於治療造血幹細胞移植相關血栓性（ｈｓｃｔ－ｔｍａ）的抗ｃ５抗體的補充劑量和投與 |
| TW202423479A (zh) | 2022-09-28 | 2024-06-16 | 美商阿雷希昂製藥公司 | 用於預防或最小化患有慢性腎病的患者中的心臟手術相關急性腎損傷（csa-aki）和/或隨後的主要不良腎事件（make）的抗c5抗體之劑量及投與 |
| WO2024238422A1 (en) | 2023-05-12 | 2024-11-21 | Alexion Pharmaceuticals, Inc. | Use of a panel of lectins for detection of complement biomarkers in urine extracellular vesicles |
| WO2024238421A1 (en) | 2023-05-12 | 2024-11-21 | Alexion Pharmaceuticals, Inc. | Use of biomarkers for the identification and treatment of complement-mediated disorders |
| WO2025058962A1 (en) * | 2023-09-11 | 2025-03-20 | Absci Corporation | High-throughput methods for kinetic characterization, quantifying and optimizing antibodies and antibody fragments expression in bacteria |
| WO2025166118A1 (en) | 2024-02-02 | 2025-08-07 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treating iga nephropathy (igan) |
| WO2025199107A1 (en) | 2024-03-19 | 2025-09-25 | Alexion Pharmaceuticals, Inc. | Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor |
| WO2025221479A1 (en) | 2024-04-16 | 2025-10-23 | Alexion Pharmaceuticals, Inc. | Biomarkers for monitoring effective treatment of neuromyelitis optica spectrum disorder (nmosd) with complement component c5 inhibitors |
| WO2025254396A1 (ko) * | 2024-06-05 | 2025-12-11 | 주식회사 이뮨앱스 | 보체 c5 결합 단백질 |
Family Cites Families (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| US5506247A (en) | 1988-04-15 | 1996-04-09 | T Cell Sciences, Inc. | Compounds that inhibit complement and/or suppress immune activity |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1992010591A1 (en) | 1990-12-14 | 1992-06-25 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| EP0571613B1 (en) | 1991-12-13 | 2003-09-17 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| DK1621554T4 (da) | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobuliner blottet for lette kæder |
| JPH08509612A (ja) | 1993-04-26 | 1996-10-15 | ジェンファーム インターナショナル インコーポレイテッド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| HUT76369A (en) | 1994-07-29 | 1997-08-28 | Smithkline Beecham Corp | Novel soluble protein compounds |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| EP0888459A1 (en) | 1996-02-02 | 1999-01-07 | Stichting Onderzoeksbeleid Cardiopulmonale Chirurgie | Measurement of complement activation by biomaterials by means of complement convertase cleavage of peptide substrates |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| US5843449A (en) | 1996-03-25 | 1998-12-01 | Akzo Nobel N.V. | Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases |
| DE69738670D1 (de) | 1996-10-28 | 2008-06-19 | Inst Suisse De Rech S Experime | Verfahren zur oligomerisation von peptiden |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| WO1998056906A1 (en) | 1997-06-11 | 1998-12-17 | Thoegersen Hans Christian | Trimerising module |
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| US6015803A (en) | 1998-05-04 | 2000-01-18 | Wirostko; Emil | Antibiotic treatment of age-related macular degeneration |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| DE60031512T2 (de) | 1999-02-19 | 2007-08-23 | University Of Iowa Research Foundation | Diagnostika und therapeutika für maculare degeneration |
| EP1804064A1 (en) | 1999-02-19 | 2007-07-04 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration |
| US7108982B1 (en) | 1999-02-19 | 2006-09-19 | University Of Iowa Research Foundation | Diagnostics and the therapeutics for macular degeneration |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| DE19932688B4 (de) | 1999-07-13 | 2009-10-08 | Scil Proteins Gmbh | Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen |
| ES2327382T3 (es) | 1999-07-20 | 2009-10-29 | Morphosys Ag | Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro. |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| WO2001014558A1 (en) * | 1999-08-26 | 2001-03-01 | Morphosys Ag | Human antibodies or fragments thereof binding to hla-cw6 |
| US7011952B2 (en) | 2000-02-22 | 2006-03-14 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration-related disorders |
| EP2213743A1 (en) | 2000-04-12 | 2010-08-04 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| JP4764590B2 (ja) | 2000-04-29 | 2011-09-07 | ユニバーシティー オブ アイオワ リサーチ ファウンデーション | 黄班変性関連疾患の診断および治療 |
| WO2001084144A1 (en) | 2000-05-04 | 2001-11-08 | Jussi Halleen | Method for in vitro screening of drug candidates useful for the prevention of bone resorption |
| CA2441903C (en) | 2000-05-26 | 2012-07-31 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
| EP2896631A1 (en) * | 2000-10-10 | 2015-07-22 | Genentech, Inc. | Inhibition of complement C5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection |
| CA2430013C (en) | 2000-11-30 | 2011-11-22 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
| AU2002307494A1 (en) * | 2001-04-24 | 2002-11-05 | Bayer Corporation | Human timp-1 antibodies |
| US20050048512A1 (en) | 2001-04-26 | 2005-03-03 | Avidia Research Institute | Combinatorial libraries of monomer domains |
| US20040175756A1 (en) | 2001-04-26 | 2004-09-09 | Avidia Research Institute | Methods for using combinatorial libraries of monomer domains |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| WO2002092780A2 (en) | 2001-05-17 | 2002-11-21 | Diversa Corporation | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof |
| CA2463879C (en) | 2001-10-25 | 2012-12-04 | Genentech, Inc. | Glycoprotein compositions |
| US7335478B2 (en) | 2002-04-18 | 2008-02-26 | Kalobios Pharmaceuticals, Inc. | Reactivation-based molecular interaction sensors |
| US20030157579A1 (en) | 2002-02-14 | 2003-08-21 | Kalobios, Inc. | Molecular sensors activated by disinhibition |
| AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
| US7816497B2 (en) | 2002-10-30 | 2010-10-19 | University Of Kentucky | Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration |
| WO2004072266A2 (en) | 2003-02-13 | 2004-08-26 | Kalobios Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
| DE10324447A1 (de) | 2003-05-28 | 2004-12-30 | Scil Proteins Gmbh | Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin |
| EP1761561B1 (en) | 2004-01-20 | 2015-08-26 | KaloBios Pharmaceuticals, Inc. | Antibody specificity transfer using minimal essential binding determinants |
| US20070116710A1 (en) | 2004-02-03 | 2007-05-24 | Leonard Bell | Methods of treating hemolytic anemia |
| US20050169921A1 (en) | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
| SG10201804008UA (en) | 2005-11-04 | 2018-06-28 | Genentech Inc | Use of complement pathway inhibitors to treat ocular diseases |
| US20070196367A1 (en) * | 2006-02-22 | 2007-08-23 | Valentin Dinu | Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system |
| US20090220508A1 (en) | 2006-03-15 | 2009-09-03 | Alexion Pharmaceuticals, Inc. | Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement |
| PY09026846A (es) * | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| ES2728278T3 (es) * | 2011-12-21 | 2019-10-23 | Novartis Ag | Composiciones que comprenden anticuerpos dirigidos al factor P y C5 |
| EP3102701A1 (en) * | 2014-02-07 | 2016-12-14 | Novartis AG | Impact of genetic factors on disease progression and response to anti-c5 antibody in geographic atrophy |
| CN116769024A (zh) * | 2016-06-14 | 2023-09-19 | 瑞泽恩制药公司 | 抗c5抗体及其用途 |
-
2009
- 2009-07-31 PY PY200909026846A patent/PY09026846A/es unknown
- 2009-08-03 SI SI200931219T patent/SI2328616T1/sl unknown
- 2009-08-03 EP EP14175574.4A patent/EP2837388A1/en not_active Withdrawn
- 2009-08-03 MY MYPI2011000242A patent/MY159396A/en unknown
- 2009-08-03 KR KR1020117005155A patent/KR101463296B1/ko active Active
- 2009-08-03 CN CN201410336233.9A patent/CN104177495B/zh active Active
- 2009-08-03 MX MX2011001371A patent/MX2011001371A/es active IP Right Grant
- 2009-08-03 WO PCT/EP2009/060052 patent/WO2010015608A1/en not_active Ceased
- 2009-08-03 EP EP14175571.0A patent/EP2815766B1/en active Active
- 2009-08-03 BR BRPI0916668-8A patent/BRPI0916668B1/pt active IP Right Grant
- 2009-08-03 ES ES14175571.0T patent/ES2643411T3/es active Active
- 2009-08-03 AR ARP090102970A patent/AR072897A1/es active IP Right Grant
- 2009-08-03 MX MX2013006207A patent/MX356218B/es unknown
- 2009-08-03 CA CA2732782A patent/CA2732782C/en active Active
- 2009-08-03 RS RS20150456A patent/RS54113B1/sr unknown
- 2009-08-03 CN CN200980138903.3A patent/CN102170906B/zh active Active
- 2009-08-03 DK DK09737379.9T patent/DK2328616T3/en active
- 2009-08-03 SG SG10201405377XA patent/SG10201405377XA/en unknown
- 2009-08-03 AU AU2009279197A patent/AU2009279197B2/en active Active
- 2009-08-03 EP EP09737379.9A patent/EP2328616B1/en active Active
- 2009-08-03 NZ NZ590634A patent/NZ590634A/en not_active IP Right Cessation
- 2009-08-03 EA EA201100300A patent/EA027575B1/ru not_active IP Right Cessation
- 2009-08-03 UA UAA201101226A patent/UA105009C2/uk unknown
- 2009-08-03 PT PT97373799T patent/PT2328616E/pt unknown
- 2009-08-03 PL PL09737379T patent/PL2328616T3/pl unknown
- 2009-08-03 HR HRP20150799TT patent/HRP20150799T1/hr unknown
- 2009-08-03 NZ NZ600622A patent/NZ600622A/en not_active IP Right Cessation
- 2009-08-03 ES ES09737379.9T patent/ES2541142T3/es active Active
- 2009-08-03 JP JP2011521555A patent/JP5815403B2/ja active Active
- 2009-08-03 PE PE2011000122A patent/PE20110225A1/es active IP Right Grant
- 2009-08-03 HU HUE09737379A patent/HUE026179T2/en unknown
- 2009-08-04 TW TW102131854A patent/TW201350130A/zh unknown
- 2009-08-04 TW TW098126209A patent/TWI417107B/zh not_active IP Right Cessation
- 2009-08-04 US US12/535,205 patent/US8241628B2/en active Active
- 2009-08-05 JO JOP/2009/0292A patent/JO3118B1/ar active
-
2011
- 2011-01-14 ZA ZA2011/00375A patent/ZA201100375B/en unknown
- 2011-01-20 IL IL210768A patent/IL210768B/en active IP Right Grant
- 2011-01-21 CR CR20110035A patent/CR20110035A/es unknown
- 2011-02-01 MA MA33575A patent/MA32535B1/fr unknown
- 2011-02-01 CO CO11011416A patent/CO6351750A2/es active IP Right Grant
- 2011-02-03 EC EC2011010805A patent/ECSP11010805A/es unknown
- 2011-02-04 CU CU2011000029A patent/CU23978B1/es active IP Right Grant
- 2011-02-04 HN HN2011000357A patent/HN2011000357A/es unknown
- 2011-02-04 CL CL2011000233A patent/CL2011000233A1/es unknown
- 2011-02-07 SV SV2011003834A patent/SV2011003834A/es unknown
- 2011-10-04 HK HK15103750.7A patent/HK1203156A1/en unknown
-
2012
- 2012-06-28 US US13/535,612 patent/US20130022615A1/en not_active Abandoned
- 2012-07-25 US US13/557,562 patent/US8883158B2/en active Active
-
2015
- 2015-04-28 US US14/698,039 patent/US20160031975A1/en not_active Abandoned
- 2015-07-21 JP JP2015143990A patent/JP6224657B2/ja active Active
-
2016
- 2016-05-04 CR CR20160206A patent/CR20160206A/es unknown
- 2016-11-17 US US15/354,978 patent/US10407496B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2328616T3 (pl) | Kompozycje i sposoby dla przeciwciał celujących białko dopełniacza C5 | |
| CY2019009I2 (el) | Αναστολεις πρωτεϊνικων κινασων | |
| CY2019014I1 (el) | Ενωσεις και συνθεσεις ως αναστολεις πρωτεϊνικης κινασης | |
| IL260285B (en) | Anti-gcc antibody molecules and related compositions and methods | |
| BRPI0820298A2 (pt) | anticorpos anti-vegf composições e métodos | |
| IL216061A0 (en) | Compositions and methods for antibodies targeting complement protein c3b | |
| PL3722310T3 (pl) | Stabilne i rozpuszczalne przeciwciała hamujące vegf | |
| IL287311A (en) | Antibodies and processes for preparing the same | |
| BRPI0911228A2 (pt) | compostos e composições como inibidores de proteínas quinase | |
| BRPI0910668A2 (pt) | inibidores de proteína quinases | |
| PT2356462T (pt) | Composições e métodos anti-cxcr1 | |
| BRPI0912198A2 (pt) | anticorpos anti-fn14 e usos dos mesmos | |
| BRPI0906877A2 (pt) | Anticorpos anti-trkb aperfeiçoados | |
| IL212175B (en) | Muc1* antibodies | |
| SMT201500082B (it) | Coniugati di oligosaccaride-proteina | |
| BRPI0920284A2 (pt) | composição e método | |
| PL3178490T3 (pl) | Kompozycje białka f rsv i sposoby ich wytwarzania | |
| DK2307543T3 (da) | Forbedret proteinekspressionssystem | |
| BRPI0921320A2 (pt) | composições de anticorpo estáveis e métodos para estabilizar os mesmos | |
| BRPI0923191A2 (pt) | metodos relacionados com glicanos modificados | |
| PT2427212T (pt) | Anticorpos anti-cd100 e métodos para utilização dos mesmos | |
| PL2488551T3 (pl) | Przeciwciała monoklonalne przeciwko progastrynie i ich zastosowania | |
| BRPI0909633A2 (pt) | anticorpos anti-tyrp1 | |
| BRPI0912769A2 (pt) | anticorpos anti-pirb | |
| BRPI0920681A2 (pt) | inibidores de decahidro-1h-indenoquinolinona e decahidro-3h-ciclopentafenantridinona de cyp17 |